Medlab Clinical Ltd. announced NanaBis (named NanaDolTM for UK purposes) has been approved by the UK Medicines and Healthcare Product Regulatory Agency (MHRA) for use in the UK Named Patient Program, and compassionate areas as an unapproved medicine, with WEP Clinical as their distribution partner. NanaDolTM (alternative UK name for NanaBis) will be provided to UK patients via doctor prescription for pain patients, including cancer bone pain, the therapeutic indication the company is most interested in. WEP Clinical is a specialist services company that works with sponsors, to help patients and physicians gain early access to unregistered medicines as appropriate. Like the Scheme Access Scheme (SAS) in Australia, patients will be charged a "compassionate" price for access to the medicine. NanaBisTM is being developed for cancer bone pain as this is a population with need of better pain management and is a relatively homogeneous cancer population that provides important characteristics conducive to successful new drug registration and commercialisation. Furthermore, extensive independent preclinical research has identified the active components of NanaBis, THC and CBD, as being particularly effective for treating cancer bone pain and a published clinical trial carried out by Professor Stephen Clarke
at RNSH showed that Bone Cancer pain patients received a strongly clinically significant (40%) reduction in pain from NanaBis.